KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $6.0 million.

  • Nektar Therapeutics' Other Operating Expenses fell 96.88% to $140,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.3 million, marking a year-over-year decrease of 166.93%. This contributed to the annual value of $6.0 million for FY2024, which is 96.19% down from last year.
  • Nektar Therapeutics' Other Operating Expenses amounted to $6.0 million in FY2024, which was down 96.19% from $156.7 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Other Operating Expenses ranged from a high of $156.7 million in FY2023 and a low of $6.0 million during FY2024.
  • Its 3-year average for Other Operating Expenses is $96.2 million, with a median of $125.9 million in 2022.
  • As far as peak fluctuations go, Nektar Therapeutics' Other Operating Expenses skyrocketed by 405.57% in 2022, and later plummeted by 96.19% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Other Operating Expenses (Yearly) stood at $64.7 million in 2020, then plummeted by 61.50% to $24.9 million in 2021, then spiked by 405.57% to $125.9 million in 2022, then grew by 24.52% to $156.7 million in 2023, then slumped by 96.19% to $6.0 million in 2024.